NCIPHER-SECURITY
24.1.2019 14:02:03 CET | Business Wire | Press release
nCipher Security , the provider of trust, integrity and control for business critical information and applications, officially launched today creating a new leader in the general purpose hardware security module (HSM) marketplace.
Today’s fast moving digital environment offers opportunities to enhance customer satisfaction, improve operational efficiency and gain competitive advantage, but in doing so also raises new security challenges. nCipher’s market-leading solutions and services allow organizations to keep pace with innovation while protecting their business critical assets from security breaches.
The world’s leading organizations have depended on nCipher nShield HSMs for more than 20 years to provide a root of trust for their business critical applications and meet their cybersecurity needs. Our customers include 5 of the top 10 Fortune 100 and 10 of the top 20 FTSE 100 companies.
Organizations are also now subject to an increasing number of strict compliance mandates such as the EU General Data Protection Regulation (GDPR), California Data Breach Notification Law and Australia Privacy Amendment Act 2017. nCipher provides the highest level of assurance in protecting sensitive data, enabling organizations to meet these very stringent compliance controls.
Cindy Provin, Chief Executive Officer, nCipher Security says:
“I
am both excited and proud to lead an innovative, agile, world-class team
helping our customers as they embrace a digital future. nCipher nShield
HSMs are a critical component in securing today’s business critical
applications as well as the journey to the cloud, new digital payment
methods and the internet of things. With high profile data breaches
hitting the headlines daily and newly enforced legislation,
organizations need to get security right.”
nCipher customers rely on nShield HSMs to provide a root of trust for a wide variety of business applications including public key infrastructures (PKIs), SSL/TLS encryption key protection, code signing, digital signing and blockchain. As growth in the Internet of Things (IoT) creates greater demand for device IDs and certificates, nShield HSMs will continue to support critical security measures such as device authentication using digital certificates.
nCipher highlights:
- World class, committed and experienced leadership team
- Exceptional technology supported by 32 patents
- 700+ years of applied cryptography and security experience
- Strong third party certifications – FIPS 140-2, eIDAS, Common Criteria
- 20-year heritage providing market-leading general purpose HSMs
- Strong installed customer base including 5 of the top 10 Fortune 100 and 10 of the top 20 FTSE 100
- Global network of strategic technology partners and distributors
nCipher Security is now a separate stand-alone business within Thales and held separate from the rest of the Thales Group pending its divestiture to a third party buyer. This results from Thales Group’s offer to acquire Gemalto and the demands of a number of antitrust agencies, including the European Commission , to create a strong player in the general purpose HSM space in order to preserve competition in this important market place and continued supply and innovations to our nShield customers. Thales and Gemalto continue to work constructively with the competent antitrust authorities to obtain the remaining merger control regulatory clearances in Russia and the United States. In addition, Thales and Gemalto are seeking regulatory clearance relating to foreign investments from the competent authority in Russia.
nCipher Security will be exhibiting at RSA Conference 2019 on booth #3106, to learn how our cryptographic solutions guard against today’s threats and attacks, enable compliance and protect your business applications.
Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.
About nCipher Security
Today’s fast moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency. It also multiplies the security risks.
nCipher Security, a leader in the general purpose hardware security module (HSM) market, empowers world-leading organizations by delivering trust, integrity and control to their business critical information and applications.
Our cryptographic solutions secure emerging technologies – cloud, IoT, blockchain, digital payments – and help meet new compliance mandates, using the same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business critical applications, ensuring the integrity of your data and putting you in complete control – today, tomorrow, at all times. www.ncipher.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190124005206/en/
Contact:
For more information please contact:
nCipher Security Megan Nemeh megan.nemeh@ncipher.com +1 408 887 5064 Liz Harris liz.harris@ncipher.com +44 7973 973648
US Media Bospar PR PRfornCipher@bospar.com
UK Media Hotwire PR nCipher@hotwireglobal.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom